Skip to main navigation
Alpine Immune Sciences Alpine Immune Sciences

Main navigation

  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Contact Us
  • Pipeline & Programs
    • Pipeline
    • Acazicolcept (ALPN-101)
    • ALPN-202
    • ALPN-303
    • Science & Platform
    • Scientific Publications
  • Clinical Trials
  • Investors
    • Stock Information
    • Analyst Coverage
    • News Release
    • Events & Presentations
    • SEC Filings
    • Governance
  • Careers
  • No menu assigned!

News Releases

Investor Relations - Horizontal

news releases  |  events  |  sec filings  |  governance  | 

board of directors  |  management team  |  documents  |  committee composition  | 

  • March 17, 2022
    Summary ToggleAlpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
    - Execution across three clinical-stage programs and addition of $176 million in committed cash in 2021 from partnerships and financing to further advance pipeline - - Davoceticept monotherapy dose escalation data to be presented at 2022 AACR Annual Meeting - - ALPN-303 phase 1 ongoing; data
    Read More
  • March 8, 2022
    Summary ToggleAlpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting
    - NEON-1 Data Selected for Minisymposium Oral Presentation - SEATTLE --(BUSINESS WIRE)--Mar. 8, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today
    Read More
  • March 7, 2022
    Summary ToggleAlpine Immune Sciences Reports FDA Partial Clinical Hold on NEON-2 Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
    -NEON-1 Study of ALPN-202 as a Monotherapy is Unaffected- SEATTLE --(BUSINESS WIRE)--Mar. 7, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today
    Read More
  • March 1, 2022
    Summary ToggleAlpine Immune Sciences Announces Participation in March Investor Conferences
    SEATTLE --(BUSINESS WIRE)--Mar. 1, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate
    Read More
  • January 4, 2022
    Summary ToggleAlpine Immune Sciences Announces Participation in January Investor Conferences
    SEATTLE --(BUSINESS WIRE)--Jan. 4, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will present at
    Read More
  • December 16, 2021
    Summary ToggleAlpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
    - Horizon will have exclusive rights to develop and commercialize up to four preclinical candidates - - Horizon will make a $40 million payment at closing, consisting of a $25 million upfront cash payment and a $15 million equity investment - - Alpine eligible to receive additional payments of up
    Read More
  • November 22, 2021
    Summary ToggleAlpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference
    SEATTLE --(BUSINESS WIRE)--Nov. 22, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at
    Read More
  • November 10, 2021
    Summary ToggleAlpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results
    - Recent private placement enables expansion and acceleration of development plans across the portfolio - - Plenary presentation for ALPN-303 at the American College of Rheumatology Convergence 2021 Annual Meeting highlighting best in class potential - SEATTLE --(BUSINESS WIRE)--Nov.
    Read More
  • November 8, 2021
    Summary ToggleAlpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting
    - ALPN-303 demonstrates superior immunomodulatory activity and efficacy in preclinical models - - Phase 1 study to begin Q4 2021 - SEATTLE --(BUSINESS WIRE)--Nov. 8, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company, today announced a presentation in
    Read More
  • September 15, 2021
    Summary ToggleAlpine Immune Sciences Announces $91 Million Private Placement
    SEATTLE --(BUSINESS WIRE)--Sep. 15, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase
    Read More

Pagination

  • First page First
  • Previous page Previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 11 - 20 of 136 results

Toolkit

  • Contact Us
  • Email Alerts
  • RSS Feeds
  • Print Page
  • Email Page

Contact

188 East Blaine Street
Suite 200
Seattle, WA
98102
206-788-4545

Sitemap

  • About Us
  • Pipelines & Programs
  • Clinical Trials
  • Investors
  • Careers
  • Contact Us
  • Legal

Twitter

@AlpineImmuneSci

LATEST TWEETS

Tweets by @AlpineImmuneSci

© 2022 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.

Investor Relations - Horizontal

  • News Releases
  • Events
  • SEC Filings
  • Governance
    • Board of Directors
    • Management Team
    • Documents
    • Committee Composition